By FieldPulse Editorial · March 5, 2026
Tags: pricing, policy, medicare
CMS named 15 drugs for Round 3 Medicare price negotiation on March 5, including Jardiance, Farxiga, Xarelto, and Ocrevus. Negotiated prices take effect January 2028.
The Centers for Medicare and Medicaid Services named 15 additional drugs for the third round of Medicare price negotiation under the Inflation Reduction Act on March 5, 2026. The list includes Jardiance (empagliflozin), Farxiga (dapagliflozin), Xarelto (rivaroxaban), and Ocrevus (ocrelizumab) among others. Negotiated prices for Round 3 drugs will take effect January 1, 2028. The inclusion of multiple blockbuster drugs with large field forces creates significant commercial uncertainty for affected companies. Boehringer Ingelheim and AstraZeneca, whose SGLT-2 inhibitors were both named, are expe